# Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg

> **NCT01376115** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 343 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Nelarabine

## Key facts

- **NCT ID:** NCT01376115
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01-18
- **Primary completion:** 2017-10-24
- **Final completion:** 2017-10-24
- **Target enrollment:** 343 (ACTUAL)
- **Last updated:** 2017-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01376115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01376115, "Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01376115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*